News

GSK raises dividend by 7% as sales decline

Country
United Kingdom

GlaxoSmithKline Plc is proposing to raise its interim dividend by 7% and continue its programme of share buybacks despite a 10% decline in sales in the 2011 first quarter. Share buybacks for the year will be at the top end of the predicted £1-£2 billion range.

Silence Therapeutics to raise up to £5.5 million in share issue

Country
United Kingdom

Silence Therapeutics Plc is proposing to raise up to £5.5 million through the issue of new shares to institutional investors and directors, and a possible additional £1 million in an open offer, which together would support its RNAi drug development platform.

Oxford Nanopore raises £25 mln in private placement

Country
United Kingdom

Oxford Nanopore Technologies Ltd announced that it has raised £25 million through a share placement with new and existing investors to support the further development of its DNA sequencing and other technologies.

Cleveland Clinic spin-out reports on heart tissue repair

Country
United States

Juventas Therapeutics, a 2007 spin-out of the Cleveland Clinic in the US, has reported the completion of a Phase 1 study of its regenerative medicine product for heart failure. No adverse events related to the treatment were reported.

FDA approves Sanofi’s Menactra for infants

Country
United States

The US Food and Drug Administration has approved Menactra, a vaccine to prevent invasive meningococcal disease, for use in children as young as nine months old. The vaccine was developed by Sanofi Pasteur.

Escitalopram approved for depression in Japan

Country
Denmark

The Japanese Ministry of Health, Labour and Welfare has approved escitalopram (Lexapro) to treat patients with depression, according to the drug’s developer, H. Lundbeck A/S. The Danish company’s partner in Japan is Mochida Pharmaceutical.

Phase 3 trial of combination paediatric vaccine starts

Country
United States

A Phase 3 trial of a combination vaccine intended to protect children against six infectious diseases is being launched at multiple sites in the US according to its sponsors, Merck & Co and Sanofi Pasteur. The trial will involve 1,440 infants.

Allogeneic cell therapy to be tested for stroke

Country
United States

The Stanford University School of Medicine, together with privately-held SanBio Inc, have started a Phase 1/2a trial of an allogeneic cell therapy on patients with stable deficits resulting from a stroke.

Legal settlement boosts Elan’s Q1 results

Country
Ireland

Elan Corporation Plc more than trebled its operating income in the 2011 first quarter following settlement of a patent suit. Revenue however was only slightly ahead as brisk Tysabri sales were nearly offset by the divestment of three legacy products.

FDA approves Rituxan for two rare disorders

Country
United States

The US Food and Drug Administration has approved Rituxan (rituximab), in combination with glucocorticoids, to treat patients with Wegener’s granulomatosis and microscopic polyangiitis, two rare disorders that cause blood vessel inflammation.